期刊
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
卷 10, 期 4, 页码 292-298出版社
SPRINGER
DOI: 10.1007/s11910-010-0113-7
关键词
Parkinson's disease; Dementia; Epidemiology; Pathology; Diagnosis; Treatment
资金
- Teva-Lundbeck
- Orion
- Boehringer-Ingelheim
- GlaxoSmithKline
- Novartis
- Eisai
- UCB
- GE
- Michael J. Fox Foundation
Dementia associated with Parkinson's disease (PDD) is a common problem and one that is associated with significant morbidity and mortality. Over the past decade, increasing research efforts and funding have been directed toward an improved understanding of PDD. Despite these efforts, fundamental gaps remain in our knowledge. Consequently, therapeutic progress has been frustratingly slow and incomplete. To significantly affect PDD, novel disease-modifying agents, rather than more traditional neurotransmitter replacement approaches, likely will be required.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据